Recursion Pharmaceuticals (RXRX) Appoints Robert Hershberg as Board Chair
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall St futures decline as US-Iran escalation rattles sentiment
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 3% as fresh military strikes threaten Hormuz shipments
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- The real reason Meta shares are surging has nothing to do with its new AI model
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
May 24, 2024 4:30 PM EDTDr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur
SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership.
Im excited to bring my clinical and scientific expertise to... More
